Skip to main content

Table 7 Lack of change in plasma AUCs (μM.h) of PR-104, PR-104A and metabolites with repeat dosing of PR-104 at 675 mg/m2 on cycle 1 day 1 (C1D1), cycle 1 day 8 (C1D8) and cycle 2 day 1 (C2D1)

From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Patient

Cycle

PR-104

PR-104A

PR-104G

PR-104H

PR-104M

PR-104S1

04-75

C1D1

6.34

12.11

6.60

0.51

0.06

0.16

 

C1D8

6.61

13.16

7.74

0.44

0.09

0.16

01-76

C1D1

6.76

14.14

21.38

0.56

0.11

0.87

 

C1D8

7.91

16.72

28.01

0.45

0.10

1.09

04-77

C1D1

14.55

17.81

7.07

0.25

0.12

0.31

 

C1D8

11.01

16.96

7.53

0.26

0.12

0.36

 

C2D1*

8.16

19.53

6.73

0.59

0.10

0.44

  1. *, given with naproxen.